logo
Summary Statement Novel Agents in the Treatment of Lung Cancer: Fifth Cambridge Conference Assessing Opportunities for Combination Therapy
Antibodies to Vascular Endothelial Growth Factor in Non-small Cell Lung Cancer
The Current Status and Evolving Role of Sunitinib in Non-small Cell Lung Cancer
Sorafenib in Lung Cancer: Clinical Developments and Future Directions
Dual Targeting of the Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor Pathways with Vandetinib (ZD6474) in Patients with Advanced or Metastatic Non-small Cell Lung Cancer
The Tyrosine Kinase Inhibitor Cediranib for Non-small Cell Lung Cancer and Other Thoracic Malignancies
DISCUSSION – ANTI-VEGF AGENTS
First-Generation Epidermal Growth Factor Receptor Inhibitors in Non-small Cell Lung Cancer: Clinical Impact of the Epidermal Growth Factor Receptor Fluorescence In Situ Hybridization Assay
First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in EGFR Mutation
Second-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer
DISCUSSION – EGFR-TARGETED AGENTS
Heat Shock Protein 90 Inhibition in Lung Cancer
K-ras as a Target for Lung Cancer Therapy
Immunotherapy for Lung Cancer
New Horizons in Chemotherapy: Platforms for Combinations in First-Line Advanced Non-small Cell Lung Cancer
DISCUSSION - OTHER LUNG CANCER TARGETS
DISCUSSION – CLINICAL TRIALS AND COMBINATION THERAPIES IN LUNG CANCER